Vismodegib, a Hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients

被引：0
|
作者：
Grob, Jean Jacques
Kunstfeld, Rainer
Dreno, Brigitte
Jouary, Thomas
Mortier, Laurent
Basset-Seguin, Nicole
Ascierto, Paolo Antonio
Hansson, Johan
Mitchell, Lada
Starnawski, Michal
Hauschild, Axel
机构：
[1] Timone Hosp, Dept Dermatol & Skin Canc, Marseille, France
[2] Med Univ Vienna, Dept Dermatol, Vienna, Austria
[3] Ctr Hosp Reg Univ Hotel Dieu, Nantes, France
[4] CHU Bordeaux, St Andre Hosp, Bordeaux, France
[5] Univ Lille 2, Lille Reg Univ Hosp, Fac Med, Dept Dermatol, Lille, France
[6] Hop St Louis, Paris, France
[7] Fdn G Pascale Ist Nazl Tumori, Naples, Italy
[8] Karolinska Univ Hosp Solna, Stockholm, Sweden
[9] F Hoffmann La Roche Ltd, Basel, Switzerland
[10] Univ Med Ctr Schleswig Holstein, Kiel, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9036
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Updated STEVIE interim analysis of Hedgehog pathway inhibitor, vismodegib, in 300 patients with advanced basal cell carcinoma
    Grob, J. -J
    Kunstfeld, R.
    Dreno, B.
    Jouary, T.
    Mortier, L.
    Ascierto, P.
    Basset-Seguin, N.
    Hansson, J.
    Mitchell, L.
    Starnawski, M.
    Hauschild, A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 107 - 108
  • [2] Visnnodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts).
    Hansson, Johan
    Hauschild, Axel
    Kunstfeld, Rainer
    Grob, Jean Jacques
    Dreno, Brigitte
    Mortier, Laurent
    Ascierto, Paolo Antonio
    Licitra, Lisa F.
    Dutriaux, Caroline
    Thomas, Luc
    Meyer, Nicolas
    Guillot, Bernard
    Dummer, Reinhard
    Arenberger, Petr
    Fife, Kate
    Raimundo, Ana
    Dika, Emi
    Dimier, Natalie
    Xynos, Ioannis
    Basset-Seguin, Nicole
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Interim analysis of STEVIE, a single-arm, open-label, multicentre study to evaluate the safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma
    Lear, J. T.
    Gore, M.
    Guerrero-Urbano, T.
    Herd, R.
    Plummer, R.
    Basset-Seguin, N.
    Hansson, J.
    Mitchell, L.
    Starnawski, M.
    Hauschild, A.
    Fife, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 : 2 - 2
  • [4] Interim analysis of STEVIE, a single-arm, open-label, multicentre study to evaluate the safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma
    Lear, J.
    Fife, K.
    Gore, M.
    Guerrero-Urbano, T.
    Herd, R.
    Plummer, R.
    Seguin, N. Basset
    Hansson, J.
    Mitchell, L.
    Starnawski, M.
    Hauschild, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 : 3 - 3
  • [5] STEVIE (Safety Events In VIsmodEgib), a single-arm, open-label study on the safety of Hedgehog Pathway Inhibitors in advanced basal cell carcinoma Vismodegib: interim analysis of 150 patients
    Gutzmer, Ralf
    Leverkues, Martin
    Garbe, Claus
    Herbst, Rudolf
    Schadendorf, Dirk
    Kunstfeld, Rainer
    Hansson, Johan
    Basset-Seguin, Nicole
    Page, Damian
    Mitchell, Lada
    Hauschild, Axel
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2012, 10 (09): : 677 - 677
  • [6] Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib
    Chang, Anne Lynn S.
    Solomon, James A.
    Hainsworth, John D.
    Goldberg, Leonard
    McKenna, Edward
    Day, Bann-mo
    Chen, Diana M.
    Weiss, Glen J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (01) : 60 - 69
  • [7] A Pivotal Multicenter Trial Evaluating Efficacy and Safety of the Hedgehog Pathway Inhibitor (HPI) Vismodegib in Patients With Advanced Basal Cell Carcinoma (BCC)
    Dirix, L.
    Migden, M. R.
    Oro, A. E.
    Hauschild, A.
    Lewis, K.
    Mueller, A. B.
    Yauch, R.
    Reddy, J. C.
    Sekulic, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : 2 - 2
  • [8] Safety and efficacy of vismodegib and impact of treatment breaks in advanced basal cell carcinoma: Interim analysis of the STEVIE study in 499 patients
    Kuntsfeld, Rainer
    Grob, Jean-Jacques
    Mortier, Laurent
    Ascierto, Paolo Antonio
    Guillot, Bernard
    Williams, Sarah
    Xynos, Ioannis
    Basset-Seguin, Nicole
    Hansson, Johan
    Hauschild, Axel
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB204 - AB204
  • [9] Vismodegib: An Inhibitor of the Hedgehog Signaling Pathway in the Treatment of Basal Cell Carcinoma
    Proctor, Amber E.
    Thompson, Lisa A.
    O'Bryant, Cindy L.
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (01) : 99 - 106
  • [10] Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update
    Sekulic, Aleksandar
    Migden, Michael R.
    Oro, Anthony E.
    Lewis, Karl D.
    Hainsworth, John D.
    Yoo, Simon
    Dirix, Luc
    Hou, Jeannie
    Yue, Huibin
    Hauschild, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345